PG
PRAH

Pendal Group’s PRA Health Sciences, Inc. PRAH Stock Holding History

Pendal Group’s Portfolio PRAH Stock Details PRAH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-696,307
Closed -$115M – 673
2021
Q2 		$115M Buy
696,307
+6,237
+0.9% +$1.04M 1.05% 32
2021
Q1 		$106M Sell
690,070
-339,963
-33% -$46.2M 1.04% 31
2020
Q4 		$129M Sell
1,030,033
-12,731
-1% -$1.42M 1.35% 17
2020
Q3 		$106M Buy
1,042,764
+16,295
+2% +$1.66M 1.29% 24
2020
Q2 		$99.9M Sell
1,026,469
-26,783
-3% -$2.49M 1.36% 18
2020
Q1 		$87.5M Buy
1,053,252
+89,942
+9% +$8.77M 1.49% 15
2019
Q4 		$107M Sell
963,310
-9,990
-1% -$1.03M 1.4% 16
2019
Q3 		$96.6M Buy
973,300
+74,313
+8% +$7.38M 1.26% 27
2019
Q2 		$78.2M Buy
898,987
+74,844
+9% +$7.14M 1.09% 30
2019
Q1 		$90.9M Sell
824,143
-59,358
-7% -$6.2M 1.25% 20
2018
Q4 		$70.5M Buy
+883,501
New +$89.4M 1.13% 31

Other funds holding PRAH

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

Pendal Group's PRAH Position: Q3 2021 in Review

Pendal Group sold out of PRA Health Sciences, Inc. (PRAH) in Q3 2021, closing a stake of 696,307 shares — an estimated $115M sold.

Pendal Group first reported a position in PRAH in Q4 2018 and held it in 11 quarters. The position peaked at $129M in Q4 2020. 1 fund tracked by Wall St. Rank holds PRAH as of Q3 2021.

  • Pendal Group reported no remaining PRA Health Sciences, Inc. position as of Q3 2021 after selling out during the quarter.
  • Pendal Group sold 696,307 PRA Health Sciences, Inc. shares in Q3 2021, an estimated $115M.
  • Pendal Group first reported a position in PRA Health Sciences, Inc. in Q4 2018 and held it in 11 quarters.
  • Pendal Group's PRA Health Sciences, Inc. position peaked at $129M in Q4 2020.
  • 1 fund tracked by Wall St. Rank held PRA Health Sciences, Inc. as of Q3 2021.

Based on Pendal Group's 13F filing for Q3 2021, filed 5 Nov 2021.